Last reviewed: June 8, 2026

Last updated: June 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide has gained attention not only for weight management but also for cardiovascular effects that researchers are actively investigating. A landmark 2023 trial showed that semaglutide reduced the risk of major adverse cardiac events by 26% in patients with established heart disease, raising questions about its role in heart failure specifically.

How Semaglutide Affects the Heart and Blood Vessels

Semaglutide works by activating GLP-1 receptors found throughout the body, including in the heart muscle and blood vessel walls. This activation triggers multiple protective pathways: improved insulin sensitivity reduces metabolic stress on the heart, weight loss decreases mechanical strain, and direct anti-inflammatory effects may reduce cardiac tissue damage. Research has shown that GLP-1 receptor stimulation improves how the heart contracts and relaxes, a property called diastolic function.

The medication also affects blood pressure and cholesterol levels independent of weight loss. In clinical trials, semaglutide users experienced average reductions in systolic blood pressure of 3–6 mmHg and improvements in triglyceride profiles. These metabolic improvements reduce the workload on the heart and may help prevent progression of heart failure, particularly in patients with obesity and metabolic syndrome.

What Research Shows About GLP-1 Drugs and Heart Failure

The SUSTAIN-6 trial (2016) demonstrated that semaglutide reduced cardiovascular death and nonfatal myocardial infarction by 26% in people with type 2 diabetes and heart disease. More recently, the 2023 American Heart Association conference highlighted secondary analyses showing potential benefits in patients with heart failure with preserved ejection fraction (HFpEF), a condition that has fewer treatment options than other heart failure types. These findings suggest GLP-1 therapy may help a specific subset of heart failure patients, though additional dedicated trials are underway.

It is important to note that semaglutide is not a primary treatment for heart failure itself. Rather, the research indicates it may provide additive protection when used alongside standard heart failure medications in patients who also have obesity or type 2 diabetes. Patients with existing heart failure should always consult their cardiologist before starting semaglutide to ensure it is appropriate for their specific condition and medication regimen.

Who May Benefit Most from Semaglutide for Cardiovascular Health

Patients most likely to benefit are those with multiple cardiovascular risk factors: obesity, type 2 diabetes, high blood pressure, or metabolic syndrome. If you have heart failure with preserved ejection fraction (HFpEF) combined with obesity, emerging research suggests semaglutide may help reduce symptoms and disease progression. Conversely, patients with heart failure with reduced ejection fraction (HFrEF) require more caution and specialist evaluation before starting GLP-1 therapy.

Genetic factors also play a role in how individuals respond to GLP-1 medications. PlexusDx's Precision Peptide Genetic Test analyzes key variants in the GLP1R and GIPR genes, as well as obesity-related genes like FTO and MC4R, to help identify which patients are more likely to experience significant cardiovascular and metabolic improvements. Understanding your genetic predisposition can inform whether semaglutide is an optimal choice for your health profile.

Getting Started with Semaglutide Through PlexusDx

PlexusDx offers compounded semaglutide injections starting at $149 per month through licensed 503A compounding pharmacies, with no insurance required and HSA/FSA eligibility. The medication is available in all 50 states, and dosing is managed by PlexusDx clinicians based on your tolerance and response. Remember: your dose may need to go up, but your price won't—PlexusDx uses flat monthly pricing regardless of dose level.

For those interested in understanding their individual response potential, the Precision Peptide Genetic Test ($99 add-on after your first month) maps 14 metabolic pathways and 49 peptides to reveal which genetic variants may influence your weight loss and cardiovascular outcomes. Combined with PlexusDx's personalized clinical support, this genetic insight helps optimize your therapy and set realistic expectations for your health journey.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I take semaglutide if I currently have heart failure?

Semaglutide is not a primary heart failure treatment, but it may be appropriate for certain patients—particularly those with HFpEF who also have obesity—when prescribed alongside standard heart failure medications and with cardiologist approval. Always disclose your heart failure diagnosis to your PlexusDx clinician before starting therapy, as individual safety assessment is essential.

What does the research actually say about semaglutide and heart failure outcomes?

The SUSTAIN-6 trial showed a 26% reduction in major adverse cardiac events in people with type 2 diabetes and existing heart disease. Recent secondary analyses suggest potential benefit in HFpEF patients, but semaglutide is not proven to treat heart failure itself—it may offer additive protection in patients with multiple risk factors when combined with standard care.

How much does semaglutide cost at PlexusDx, and is it covered by insurance?

PlexusDx compounded semaglutide injections start at $149 per month on a flat-rate model—your price remains the same whether your dose increases. Insurance is not required, though the medication is HSA/FSA eligible. All prescriptions are filled by licensed 503A compounding pharmacies and available across all 50 states.

Are there any heart-related side effects or safety concerns with semaglutide?

Semaglutide is generally well-tolerated with a strong cardiovascular safety profile. Common side effects like nausea are gastrointestinal and typically mild. However, rapid weight loss can occasionally affect fluid balance, so patients with heart failure should be monitored closely. Your PlexusDx clinician will screen for contraindications and adjust therapy accordingly.

How does the PlexusDx Precision Peptide Genetic Test help predict my response to semaglutide?

The test analyzes variants in GLP1R, GIPR, FTO, and MC4R genes—key players in appetite regulation and metabolic response. This genetic mapping across 14 pathways and 49 peptides reveals your individual predisposition to weight loss and cardiovascular improvement, helping PlexusDx clinicians personalize your semaglutide protocol for optimal outcomes.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves